What OxyLo Inc. is building
OxyLo develops enzyme-loaded embolic microspheres that enhance targeted cancer therapy by converting prodrugs into active chemotherapy directly at the tumor site. Its ProCaps platform aims to improve transarterial chemoembolization (TACE) for hepatocellular carcinoma treatment.
Pitch Pulse context
OxyLo Inc. is part of Pitch Pulse's published Bio finalist cohort and is recognized as a session winner.
